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ABSTRACT: Surfactant protein D (SP-D) is a collectin that plays an
important role in the innate immune system and takes part in the
surfactant homeostasis by regulating the surfactant pool size. The
aims of this study were to investigate the values of SP-D in umbilical
cord blood and capillary blood of premature infants and to relate the
levels to perinatal conditions. A total of 254 premature infants were
enrolled in the present study. Umbilical cord blood was drawn at the
time of birth and capillary blood at regular intervals throughout the
admission. The concentration of SP-D in umbilical cord blood and
capillary blood was measured using ELISA technique. The median
concentration of SP-D in umbilical cord blood was twice as high as
in mature infants, 769 ng/mL (range 140–2,551), with lowest values
in infants with intrauterine growth retardation (IUGR) and rupture of
membranes (ROM). The median concentration of SP-D in capillary
blood day 1 was 1,466 ng/mL (range 410–5,051 ng/mL), with lowest
values in infants born with ROM and delivered vaginally. High SP-D
levels in umbilical cord blood and capillary blood on day 1 were
found to be more likely in infants in need for respiratory support or
surfactant treatment and susceptibility to infections. We conclude
that SP-D concentrations in umbilical cord blood and capillary blood
in premature infants are twice as high as in mature infants and depend
on several perinatal conditions. High SP-D levels in umbilical cord
blood and capillary blood on day 1 were found to be related to
increased risk of RDS and infections. (Pediatr Res 59: 806–810,
2006)
Respiratory distress syndrome (RDS) is a main contributorto increased mortality and morbidity among premature
infants. RDS is caused by lack of pulmonary surfactant lead-
ing to atelectasis and ventilation-perfusion mismatch of the
lungs (1). Biochemically, pulmonary surfactant is a mixture of
phospholipids and associated proteins which are synthesized,
stored, secreted and recycled by type II cells in the airways
(2). This mixture forms a monolayer at the air-liquid interface
which lowers the surface tension, stabilizes alveoli and termi-
nal airways at low lung volume and prevents alveolar collapse
at the end of the expiration. Treatment with synthetic or
naturally developed surfactant has been associated with a
decline in the mortality of RDS among premature infants
(3,4).
Four specific surfactant proteins have been identified, called
surfactant protein (SP) A-D. SP-B and SP-C have been char-
acterized as hydrophobic polypeptides that enhance the ad-
sorption of lipid to the surface of the alveoli (5), while SP-A
and SP-D are hydrophilic and participate in the innate host
defense immune system. SP-D binds to macrophages and
neutrophils and promotes phagocytosis and killing of bacteria,
fungi, and viruses (6). Polymorphism in the amino acid resi-
due 11 of the SPD gene has been found to increase severity of
respiratory syncytial virus infection and susceptibility to tu-
berculosis (7,8).
SP-A and SP-B are instrumental in surfactant storage in
lamellar bodies and in the formation of tubular myelin and
surfactant monolayer (9). The role of SP-D in surfactant
homeostasis is not yet fully understood. SP-D knockout mice
however, accumulate phospholipids in the alveolar space lead-
ing to emphysematous changes (10) and increased suscepti-
bility to infections (6). SP-D regulates the surfactant pool size
by influencing the surfactant ultrastructure and its reuptake in
type II cells (11). SP-D is a large, complex glycoprotein with
monomeric structure forming trimers that cluster to form a
quaternary cruciate structure (12).
SP-D plays an important role in the innate immune system.
In premature infants the innate immune system is especially
important, since efficient transfer of maternal antibodies oc-
curs only after 34 wk of gestation, leading to low levels of IgG
at birth in premature infants (13). SP-D in bronchoalveolar
lavage increases during the first days of life in prematurely
born infants, and low concentration of SP-D was found to
predict worse clinical outcome (14). The levels of SP-A in
cord blood has been found to predict RDS among prematurely
born infants (15). We have demonstrated that levels of SP-D
in cord blood and capillary blood of mature newborn infants
depend on several maternal and perinatal conditions (16)
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including labor, mode of delivery and maternal smoking. In
this study we report, to our knowledge for the first time, cord
blood and capillary blood levels of SP-D in premature infants
and their influence on respiratory distress syndrome and sus-
ceptibility to neonatal infections.
MATERIALS AND METHODS
Subjects. From August, 2000 to January, 2002, prematurely born infants
with gestational age  36 wk were included in the present study. The infants
were born at Odense University Hospital or transferred from district hospitals
shortly after birth. Infants with major anomalies and missing informed
consent from the parents were excluded. Umbilical cord blood was drawn
from infants born at our hospital immediately after birth. The midwives were
instructed to draw blood preferably from the umbilical artery.
Capillary blood was sampled daily when routine blood sampling was done
until the infant was stable, then weekly. The capillary blood was sampled by
heel-prick. All samples were stored at 20°C until measurement of SP-D.
The infants were treated according the clinic’s usual guidelines with early
nasal continuous positive airway pressure (CPAP) (17) and early rescue
surfactant (18).
Methods. SP-D concentrations in plasma were measured by ELISA. The
assay is based on pepsin-digested polyclonal rabbit anti-SP-D antibody as first
layer antibody and monoclonal anti-SP-D antibody as detector antibody as
described earlier (19). The samples were tested in duplicates and accepted
with a coefficient of variation of 5%.
Statistics. Data were analyzed using the STATA program. Mann-Witney
U-test was used to compare levels of SP-D between two groups, and non-
parametric test for trend across ordered groups for more than two groups.
Wilcoxon sign rank test was used to analyze paired data. The variance
between SP-D levels in arterial, venous and capillary blood was tested using
Bland-Altman’s plot with Pitman’s test of difference in variance. Correlations
between continuous variables and SP-D levels were analyzed by simple
regression analysis. In all statistical methods, p  0.05 were considered
significant. Results are expressed as medians (range) unless otherwise noted.
Ethical considerations. Written informed consent was given for every
child enrolled in the study. The study was conducted according to the Helsinki
II recommendations and was approved by the Regional Committee for
Research on Human Subjects in the Counties of Funen and Vejle.
RESULTS
A total of 254 infants with gestational age 322 weeks
(235–356) were included in the study out of a number of 276
premature infants treated in Odense University Hospital dur-
ing this time period. The clinical data are shown in Table 1.
Umbilical cord blood was drawn from 165 of the infants. The
levels of SP-D in these samples was 769 ng/mL (140–2,551).
The SP-D level in umbilical cord blood did not depend on
gestational age. The reasons for missing umbilical cord blood
samples were in 60 cases infants transferred to the institution
after birth, and 39 infants from whom no blood could be
drawn from the umbilical cord. The umbilical cord blood was
sampled from the arterial side in 71 infants. There was no
significant difference between the arterial SP-D levels, 705
ng/mL (140–2,551) and the venous SP-D levels, 806 ng/mL
(176–2,079). The SP-D levels in umbilical cord blood were
lower in infants with intrauterine growth retardation (IUGR)
and rupture of membranes (ROM) (Table 2).
The population of infants had in median five capillary
samples drawn (1–29) during their admission. There was a
good correlation between umbilical cord blood levels and the
measured capillary levels throughout the first 35 d (p 
0.0001). The SP-D levels in capillary blood from the first day
Table 1. Clinical data of the study population of premature infants (GA 23–36 weeks)
Gestational age 23–28 weeks
N  44
Gestational age 29–32 weeks
N  75
Gestational age 33–36 weeks
N  135
Gestational age (weeks) 265 (235–280) 311 (281–320) 340 (321–356)
Birth weight (g) 804 (454–1,400) 1,586 (880–2,118) 2,091 (1,142–3,327)
Sex female/male (% female) 19/25 (43.2%) 37/38 (49.3) 62/73 (45.9)
Maternal age (years) 31 (20–40) 27 (20–42) 30 (18–42)
Maternal smoking (n %) 10 (28.6%) 15 (23.4%) 27 (22.7%)
Maternal steroid (n %) 38 (86.4%) 67 (90.6%) 73 (54.5%)
Caesarean section (n %) 31 (70.5%) 52 (69.3%) 88 (65.2%)
IUGR (n %) 5 (11.4%) 21 (28.0%) 39 (28.9%)
Labor (n %) 21 (52.5%) 43 (58.1%) 69 (51.1%)
Duration (hours) 2 (1–12) 5 (1–24) 4 (1–21)
PROM (n %) 14 (31.8%) 21 (28.0%) 47 (34.8%)
Duration (hours) 43 (2–600) 65 (1–2,100) 7 (1–192)
SP-D level in umbilical blood 814 (185–2,269) 706 (176–2,225) 769 (140–2,551)
SP-D level on day 1 1,774 (410–3,639) 1,398 (410–3,639) 1,466 (615–5,051)
SP-D level on day 7** 2,269 (583–14,120) 1,921 (658–8,178) 1,182 (399–11,027)
SP-D level on day 14** 3,078 (399–11,027) 1,666 (517–6,460) 1,167 (517–6,460)
SP-D level on day 21** 2,454 (1,072–5,081) 1,625 (681–5,553) 1,249 (516–3,645)
Surfactant treatment (n %) 22 (50.0%) 6 (8.0%) 6 (4.4%)
Antibiotics (n %) 36 (81.8%) 25 (33.3%) 18 (13.3%)
Septicemia (n %) 17 (38.6%) 4 (5.3%) 2 (1.5%)
CPAP (n %) 44 (100.0%) 70 (94.4%) 74 (54.8%)
Duration (days) 55 (9–74) 4 (1–74) 2 (1–10)
Oxygen (n %) 26 (86.7%) 24 (33.3%) 21 (15.6%)
Duration (days) 57 (2–94) 6 (1–94) 2 (1–14)
Ventilator (n %) 10 (33.3%) 2 (2.8%) 2 (1.5%)
Duration (days) 5 (1–20) 4 (4–4) 2.5 (2–3)
Death (n %) 14 (31.8%) 3 (4.0%) 0
** p  0.01 non-parametric test for trend across ordered groups.
Values given as median (range) unless otherwise stated.
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of life were significantly lower in infants with ROM, after
vaginal delivery or when the infants were born by mothers
who smoked (Table 2).
The capillary SP-D levels on day 1 was 1,466 ng/mL
(410–5,051) and increased to 1,788 ng/mL (374–13,154) on
day 4, and then decreased during the next week (Fig. 1).
However, this alteration was only found in infants requiring
ventilatory support, i.e., oxygen, CPAP or ventilator treatment
(Fig. 2). From day 1 till day 49 the SP-D levels in infants with
need of respiratory support (data shown for oxygen only) were
significantly increased.
The SP-D levels in capillary blood on day 1 in the 34 (13%)
infants treated with surfactant were significantly higher than
the levels in infants not treated (Table 3), but there was no
difference in the umbilical cord levels. Of the survivors, 172
(73%) were treated with CPAP, 71 (30%) with oxygen and 14
(6%) needed ventilator treatment. Their SP-D levels in capil-
lary blood on day 1 were significantly higher than the levels
observed in infants without need of respiratory support, and
the SP-D levels in umbilical cord blood were increased in
infants later treated with oxygen. Notably, the SP-D levels in
umbilical cord blood and on day 1 were significantly higher
among the 23 (9%) infants who developed septicemia later
during the admission. These infants developed septicemia
with a median of day 11 (range 1–42). The higher levels were
seen independently of the time interval to development of
septicemia.
The SP-D levels in the 12 (5%) infants who developed
chronic lung disease (CLD), with need of oxygen at 36 wk
gestational age, were not increased in umbilical cord blood or
capillary blood on day 1, but at age 36 wk the levels were
significantly increased (p  0.001).
The SP-D levels in the 17 (6.7%) non-surviving infants
were not significantly different from levels in survivors. Four
of the infants died within 24 h. Their SP-D levels in umbilical
cord blood tended to be lower, 407 ng/mL (191–1083), than in
the 13 infants who died later, 814 (209–1,611).
DISCUSSION
We have recently demonstrated that SP-D levels in cord
blood and capillary blood of mature infants are influenced by
mode of delivery, labor and maternal smoking (16). In this
study we have determined the levels of SP-D in prematurely
born infants. We found that the levels of SP-D both in
umbilical cord blood and capillary blood were highly variable
Table 2. SP-D levels ( ng/mL ) in relation to maternal and obstetrical conditions
Variable Yes/no (n)
SP-D in cord blood SP-D in capillary blood first day of life
Yes No p Yes No p
Maternal smoking 52/166 805 (566–927) 759 (660–890) 0.68 1413 (1072–1649) 1834 (1597–2141) 0.04*
Maternal steroid§ 178/74 705 (615–868) 830 (723–955) 0.15 1787 (1492–2024) 1397 (1195–1708) 0.07
Labor 133/116 769 (697–861) 720 (603–923) 0.49 1466 (1334–1817) 1748 (1476–1988) 0.12
ROM 82/172 604 (475–783) 835 (734–1012) 0.011* 1403 (1034–1578) 1825 (1588–2137) 0.0015†
CS 171/83 769 (665–879) 760 (606–952) 0.85 1748 (1462–1912) 1466 (1315–1926) 0.0049†
Male 136/118 716 (649–903) 779 (643–931) 0.62 1566 (1386–1796) 1799 (1455–2111) 0.73
IUGR 65/189 524 (379–759) 822 (712–956) 0.0042† 1466 (1370–1782) 1762 (1455–1994) 0.26
SP-D levels as median (lower and upper limit of 95% confidence interval).ROM, rupture of membrane for more than 1 hour before birth; CS, caesarean section;
IUGR, intrauterine growth retardation.
§ one or two doses betamethasone before birth.
Values are compared by Mann-Whitney U-test * p  0.05, † p  0.005.
Figure 1. Capillary SP-D levels on days 1–14. Capillary SP-D levels in-
creased significantly from day 1 to day 4, then decreased until day 14. Values
are given as median (95% confidence interval). * p  0.005, ** p  0.0005,
compared with day 1, Wilcoxon paired-sample test. n  254.
Figure 2. Capillary SP-D levels on days 1–77 in infants with (E˙ ) (n  71)
and without () (n  166) need of oxygen. Capillary SP-D levels in infants
with need of oxygen increased rapidly until day 4 and then slowly decreased.
The values were significantly higher than values for infants without oxygen
from day 1 to day 49. Values are given as median (95% confidence interval).
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and depended on several perinatal conditions. Furthermore,
we observed that the SP-D levels were related to morbidity in
prematurely born infants.
RDS is a major cause of increased morbidity and mortality
among premature infants. This clinical entity is caused by lack
of pulmonary surfactant, leading to collapse of the alveoli and
damage to the alveolar septae. We found high SP-D capillary
levels in infants in need of oxygen or CPAP treatment and in
infants treated with surfactant. Increased levels of SP-D are
also found in adults with acute and chronic lung injury (20)
and children with interstitial lung disease (21). These findings
may at least partly be due to the alveolar-to-vascular leakage
of surfactant proteins from the alveoli to the bloodstream (22).
Increased permeability of the lung vessels leads to leakage of
serum proteins into the alveoli, resulting in inactivation of the
surfactant (23) and further lack of surfactant at the alveolar
membrane. Elevations of SP-D in the serum could also reflect
increased type II cell activity as a reparative process following
lung injury with a resultant leak back into the blood (24).
SP-D is mainly produced in the epithelial cells in the lungs,
but is also found in epithelial cells and secretory glands in the
gastrointestinal tract and in other tissues (25). The contribu-
tion of this production to the values measured in serum is not
known.
Exposure of rats to hyperoxia leads to increased expression
of SP-D mRNA, but to decreased amount of immunodetect-
able SP-D in lung tissue (26), leading to the assumption that
SP-D is excreted into the alveolar space and from there enters
the circulation. The increase in SP-D is therefore probably due
to both capillary leak and increased release of SP-D from
epithelial cells due to the inflammatory response (19). Me-
chanical ventilation of the lungs has been shown to modulate
SP-D gene expression and increase SP-D production (27) and
probably the pressure delivered to the lungs by the nasal
CPAP used to treat respiratory distress (28) has the same
effect.
SP-D regulates the surfactant pool size by influencing the
surfactant ultrastructure and its reuptake in type II cells (11).
SP-D does not localize to lamellar bodies, but can, in absence
of SP-A, form atypical but highly surface-active tubular ag-
gregates by binding phosphatidylinositol, a component of
mammalian surfactant that is increased in lung damage (29).
Low levels of SP-D in bronchial lavage have been found to
predict bad outcome and increased susceptibility to infections
(14). We found markedly increased levels of SP-D in umbil-
ical cord blood and capillary blood on the first day of life in
infants that later developed sepsis independent of interval
between birth and the diagnosis of septicemia. This finding is
consistent with our data obtained in mature newborn infants
(16). One could speculate that the high SP-D levels were due
to an increased capillary leak leading to decreased levels of
SP-D in the lungs. Such an effect may add to the newborn’s
susceptibility to infections as observed experimentally in pre-
mature baboons (30). However, this explanation does not take
into account the higher levels found in umbilical cord blood
before breathing is started. There is some evidence that alve-
olar-vascular permeation is influenced by the degree of lung
maturation (24). One could speculate that the lungs of the
infants who later develop septicemia have less mature alveo-
lar-vascular integrity and that the leakage of proteins into the
circulation therefore takes place before birth.
The SP-D levels in umbilical cord blood from premature
infants were twice as high as in mature infants, and did not
decrease with gestational age as we previously described in
mature infants for gestational age 36–43 wk (16). These data
suggest that the decrease in SP-D levels occurs late in preg-
nancy. The production of SP-D in fetal human lungs begins in
the bronchiolar and terminal epithelium from about 21 wk of
gestation (31). Several studies of human fetuses show low
production of SP-D in the lungs and amniotic fluid in early
gestation, increasing through gestation, but decreasing late in
gestation (32–34). Besides the lungs, SP-D is synthesized in
various exocrine ducts, the mucosa of the gastrointestinal and
genitourinary tracts and placenta (25,34). The high blood
levels found in premature infants in our study may therefore
be due to relative larger production in placenta and other
extra-pulmonary tissue.
IUGR is often the result of a poorly functioning placenta,
and SP-D is synthesized in the trophoblast sub-populations in
the placenta (34). However, we found low levels of SP-D not
only in venous cord blood, but also in arterial cord blood,
indicating that also the infants’ production is decreased as a
consequence of IUGR. IUGR is found to decrease production
rates of lung saturated phosphatidylcholine (35) and the pro-
Table 3. SP-D levels (ng/mL) in umbilical cord blood and capillary blood on first day of life in relation to neonatal conditions
Variable Yes/no (n)
Cord blood Day 1
Yes No p Yes No p
Curosurf 34/220 884 (376–1,110) 737 (666–835) 0.92 2,662 (1,961–3,529) 1,467 (1,380–1,753) 0.0001†
CPAP§ 172/65 835 (729–973) 675 (475–807) 0.08 1,810 (1,554–2,164) 1,147 (876–1,508) 0.0002†
Oxygen§ 71/166 959 (771–1,332) 698 (634–818) 0.04* 2,592 (2,123–3,119) 1,386 (1,257–1,456)  0.0005†
Ventilator§ 14/223 923 (772–1,665) 759 (670–855) 0.20 2,965 (1,680–3,419) 1,569 (1,397–1,793) 0.02*
Septicemia 23/231 1,064 (832–1,354) 718 (650–824) 0.04* 2,187 (1,838–3,187) 1,569 (1,396–1,777) 0.009**
CLD§ 12/225 847 (319–1,544) 764 (681–865) 0.90 1,790 (839–3,489) 1,592 (1,414–1,825) 0.61
Death 17/237 454 (252–1,255) 769 (684–867) 0.22 1,813 (1,422–2,531) 1,592 (1,432–1,827) 0.51
SP-D levels as median (lower and upper limit of 95% confidence interval).
CLD, chronic lung disease with need of oxygen at 36 weeks of gestational age.
Values are compared by Mann-Whitney U test * p  0.05, ** p  0.01, † p  0.005.
§ among survivors.
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duction of total lung liquid (36). The low production is
probably due to diminished amounts of substrates.
The capillary SP-D levels the first day of life were twice as
high as the umbilical cord blood levels. The levels of SP-D in
the lungs of newborn infants have been found to rise signifi-
cantly the first days of life (14). This could be due to the
physiologic re-absorption of lung liquid across the pulmonary
epithelium to the circulation during the start of the respiration
(37).
Smoking during pregnancy decreases trophoblast prolifer-
ation and reduces the length of villous capillaries in the
placenta leading to diminished area for gas and nutrients
exchange (39,40). Recently we have shown by immunohisto-
chemical analysis that SP-D is synthesized in all villous and
extravillous trophoblast sub-populations in the placenta (34).
Consistent with this, we have demonstrated decreased SP-D
levels in umbilical venous blood in mature infants of smoking
mothers (16). However, in the present study the SP-D levels of
infants from smoking mothers were only lower in capillary
blood and not in umbilical venous cord blood.
In summary, we have in this study determined normal levels
of SP-D in blood of premature infants. Perinatal events may
influence SP-D levels both in umbilical and capillary blood in
opposing directions. High levels of SP-D in umbilical blood
and capillary blood day 1 indicate development of RDS and
susceptibility to infection. A study of the connection between
genetic polymorphisms, SP-D levels in blood and clinical
symptoms are in progress. Further studies are needed to clarify
if SP-D can be used as a prognostic marker in premature
infants.
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